Log in

Agios Pharmaceuticals Stock Forecast, Price & News

+0.57 (+1.68 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $34.44
50-Day Range
MA: $39.55
52-Week Range
Now: $34.44
Volume867,885 shs
Average Volume677,364 shs
Market Capitalization$2.38 billion
P/E RatioN/A
Dividend YieldN/A
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
Read More
Agios Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AGIO



Sales & Book Value

Annual Sales$117.91 million
Book Value$10.88 per share


Net Income$-411,470,000.00
Net Margins-182.49%


Market Cap$2.38 billion
Next Earnings Date10/29/2020 (Estimated)
+0.57 (+1.68 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

How has Agios Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AGIO shares have decreased by 15.7% and is now trading at $34.44.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Agios Pharmaceuticals?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Agios Pharmaceuticals

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Agios Pharmaceuticals

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals Inc (NASDAQ:AGIO) issued its earnings results on Thursday, July, 30th. The biopharmaceutical company reported ($1.31) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.36) by $0.05. The biopharmaceutical company had revenue of $37.30 million for the quarter, compared to analyst estimates of $37.17 million. Agios Pharmaceuticals had a negative net margin of 182.49% and a negative return on equity of 59.71%. The business's quarterly revenue was up 42.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.87) earnings per share.
View Agios Pharmaceuticals' earnings history

What price target have analysts set for AGIO?

14 analysts have issued twelve-month price targets for Agios Pharmaceuticals' shares. Their forecasts range from $49.00 to $82.00. On average, they anticipate Agios Pharmaceuticals' share price to reach $69.83 in the next twelve months. This suggests a possible upside of 102.8% from the stock's current price.
View analysts' price targets for Agios Pharmaceuticals

Who are some of Agios Pharmaceuticals' key competitors?

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Celgene (CELG), Alibaba Group (BABA), Micron Technology (MU), bluebird bio (BLUE), NVIDIA (NVDA), Tesla (TSLA), Vertex Pharmaceuticals (VRTX), Intercept Pharmaceuticals (ICPT) and Netflix (NFLX).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the following people:
  • Jacqualyn A. Fouse, Chief Executive Officer & Director
  • Andrew J. Hirsch, CFO & Head-Corporate Development
  • Scott Biller, Chief Scientific Officer
  • Chris Bowden, Chief Medical Officer
  • Clive Patience, Senior Vice President-Technical Operations

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.31%), FMR LLC (8.13%), Bellevue Group AG (5.82%), Goldman Sachs Group Inc. (2.88%), First Trust Advisors LP (2.31%) and Macquarie Group Ltd. (1.78%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, Jacqualyn A Fouse, Scott Biller and Steven L Hoerter.
View institutional ownership trends for Agios Pharmaceuticals

Which major investors are selling Agios Pharmaceuticals stock?

AGIO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Goldman Sachs Group Inc., Jennison Associates LLC, Bank of America Corp DE, UBS Group AG, Canada Pension Plan Investment Board, ArrowMark Colorado Holdings LLC, and Artal Group S.A.. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, and Christopher Bowden.
View insider buying and selling activity for Agios Pharmaceuticals

Which major investors are buying Agios Pharmaceuticals stock?

AGIO stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Great Lakes Advisors LLC, Point72 Asset Management L.P., Peregrine Capital Management LLC, Bellevue Group AG, Man Group plc, Macquarie Group Ltd., and Alyeska Investment Group L.P.. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse.
View insider buying and selling activity for Agios Pharmaceuticals

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $34.44.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $2.38 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.

What is Agios Pharmaceuticals' official website?

The official website for Agios Pharmaceuticals is www.agios.com.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.